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Introduction: Pelvic floor muscle training (PFMT) involves the contraction of 
the puborectal, anal sphincter and external urethral muscles, inhibiting the 
detrusor contraction, what justify its use in the treatment of overactive bladder 
(OAB) symptoms. 
Objective: To verify the effects of isolated PFMT on the symptoms of OAB. 
Method: Prospective clinical trial with 27 women with mixed urinary incontinence 
(MUI), with predominance of OAB symptoms and loss ≥ 2 g in the pad test. It 
was evaluated: pelvic floor muscles (PFMs) function (digital palpation and 
manometry); urinary symptoms (nocturia, frequency and urinary loss); degree 
of discomfort of OAB symptoms; and quality of life (Incontinence Quality-of-
Life Questionnaire [I-QoL]). The PFMT program consisted of 24 outpatient 
sessions (2x/week + home PFMT). The Mann-Whitney and Wilcoxon tests (with 
a significance level of 5%) were used to analyse the data. 
Results: There was a significant improvement of the urinary symptoms to the 
pad test (5.8±9.7, p<0.001), urinary loss (0.7±1.1, p=0.005) and nocturia (0.8±0.9, 
p=0.011). Reduction in the degree of discomfort of urinary symptoms was 
observed according to OAB-V8 questionnaire (10.0±7.7, p=0.001). There were 
also significant results in PFMs function: Oxford (3.6±0.9, p=0.001), endurance 
(5.2±1.8, p<0.001), fast (8.9±1.5, p<0.001) and manometry (26.6±15.8, p=0.003). 
In addition, quality of life had a significant improvement in the three domains 
evaluated by I-QoL. 
Conclusion: The PFMT without any additional guidelines improves the 
symptomatology, the function of PFMs and the quality of life of women with 
OAB symptoms.
Keywords: urinary incontinence, pelvic floor, physical therapy modalities. 
introduction
Overactive bladder (OAB) syndrome, also know as ur-
gency syndrome or urgency-frequency syndrome, is a 
clinical diagnosis characterized by voiding urgency, with 
or without urgency urinary incontinence (UUI), usually 
accompanied by nocturia and increased voiding frequen-
cy, in the absence of infectious or metabolic factors.1 
OAB symptoms compromise quality of life, causing 
social isolation, a decline in productivity, shame, frustra-
tion, anxiety and low self-esteem.2 Symptoms include 
increased voiding frequency, present in approximately 
85% of patients, followed by urgency, present in 54%.3 
UUI, in turn, is present in one third of the patients.4 En-
uresis, nocturia and urinary leakage due to stress incon-
tinence are also reported.5
The main therapeutic modalities are conservative 
therapies, such as pharmacological treatment and behav-
ioral therapy. Behavioral therapy includes the association 
of various resources, such as: educational program; chang-
es in lifestyle; bladder training and urge suppression strat-
egies; pelvic floor muscle training (PFMT); electro-stim-
ulation; and programmed urination.6-8 
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The effects of behavioral therapy in the treatment of 
OAB symptoms are extensively studied and their efficacy, 
proven.9 The literature investigating the effects of PFMT 
on OAB symptoms, without the association of other tech-
niques, is scarce. The justification for using PFMT is that 
PFM contraction inhibits detrusor contraction, thus 
improving the symptoms of detrusor overactivity.10 Ac-
cordingly, our main question is: Does PFMT alone result 
in improved symptoms of detrusor overactivity? Second-
arily, we assessed the PFM function and the quality of life 
of women with OAB symptoms.
Method
Study design and population
This is a prospective clinical trial conducted from March 
2011 to September 2013. The study was developed at the 
Urogynecology and Vaginal Surgery Unit of the General 
Gynecology Division, Department of Gynecology, at Uni-
versidade Federal de São Paulo (Unifesp). The Unifesp 
Research Ethics Committee granted approval for the study 
(protocol number CEP 1981/10). All participants signed the 
Voluntary Informed Consent Form, drafted in accordance 
with Resolution No. 196/96 of the National Health Council. 
We included women with a history of mixed urinary 
incontinence (MUI) who reported OAB symptoms, with 
urinary leakage ≥ 2 g on the standardized volume pad test 
during medical appointment. Exclusion criteria were 
chronic-degenerative diseases; greater than grade II pelvic 
organ prolapse; urinary tract infection; neurological or 
psychiatric disease; present or past use of anticholinergics 
and tricyclic antidepressants during up to 6 months; or 
previous PFM training.
Once the participants were included, we initially col-
lected their socio-demographic (age) and clinical (body 
mass index and urinary leakage time) information, as well 
as obstetric history (parity, vaginal delivery). Subsequent-
ly, the participating women were referred to a physio-
therapist specialized in urogynecology, who assessed PFM 
function, urinary symptoms and quality of life. 
PFM function assessment
PFM function was assessed by digital palpation, according 
to the PERFECT scheme. The Oxford scale was used for 
quantifying muscle strength. It assesses muscle strength 
from 0 to 5. Muscle endurance and rapid contractions 
were also assessed by means of the PERFECT system, an 
acronym meaning: Power (P), Endurance (E) and Fast (F), 
i.e. number of fast contractions.11 
After digital examination, the maximum voluntary 
contraction (MVC) pressure of the pelvic floor muscles 
was assessed using a Peritron manometer (Cardio Design™, 
Victoria, Austrália). It is a conical vaginal catheter that is 
connected to a hand-held microprocessor with a latex 
tube, which allows pressure readings to be transmitted 
in centimeters of water (cmH2O) when the catheter is 
compressed due to external pressure. The catheter was 
covered with a sterile condom and inserted into the vag-
inal canal until the entire length of the compressible part 
of the device was above the level of the hymenal annulus. 
The baseline pressure reading was recorded, and the cath-
eter was then inflated to 100 cmH2O and the device was 
then set to zero. Participants were requested to hold three 
consecutive MVCs, with a 10-second interval between 
each contraction12 and the best of three was recorded.13
Assessment of urinary symptoms
OAB syndrome was assessed based on the Overactive Blad-
der Questionnaire (OAB-V8). This scale includes items on 
urgency, incontinence, nocturia and voiding frequency, as 
defined by the International Continence Society (ICS), 
referring to the previous four weeks. The final score is the 
sum of the partial scores obtained for each of the eight 
questions, ranging from 0 to 40. Patients with a final score 
of eight or more are considered as having OAB symptoms.14
Patients were also instructed to keep a voiding diary 
for seven days. In this diary, diurnal urinary frequency, 
nocturia and urinary leakage in situations of stress (cough-
ing, sneezing, laughing, squatting, weight lifting, walking, 
and running) were recorded.15
We also conducted a standardized bladder volume 
pad test in order to analyze the severity of urinary incon-
tinence. Firstly, the bladder was emptied with a catheter, 
and 250 mL of injection water were then infused. The 
participants used pre-weighted sanitary napkins and did 
the following physical activities: ten jumps, ten squats, 
ten coughs, climb and descend five flights of stairs ten 
times, walking for 15 minutes and washing hands for one 
minute. After the activities were completed, the pads were 
weighed again to determine the amount of leakage.16 
Assessment of quality of life
The impact of OAB syndrome symptoms on quality of life 
was assessed based on the Incontinence Quality-of-Life 
(I-QoL) Questionnaire. The I-QoL Questionnaire consists 
of 22 questions that assess the limitations on human be-
havior, the psychosocial impact and social constraint brought 
about by urinary incontinence. Responses are given on a 
scale ranging from 1 to 5 points and the final scores are 
then summed up and converted into percentages. The 
higher the percentage, the better the quality of life.17
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PFM training protocol
The treatment consisted of outpatient sessions conduct-
ed under the supervision of the physiotherapist (24 out-
patient sessions of 40 minutes each) and home training 
for 12 weeks.
A program consisting of three sets of ten repetitions 
per day was prescribed. The treatment protocol was per-
sonalized and based on the initial evaluation as assessed 
by PERFECT. We instructed our patients to contract and 
hold the contraction for some seconds (the time corre-
sponds to the reading obtained during the initial assess-
ment – from 1 to 10 seconds), which were then followed 
by fast contractions (calculated in the same way). One 
series of exercises consisted of ten repetitions of each 
movement (endurance + rest + fast contractions). For 
example, if 6 seconds of muscle endurance and three fast 
muscle contractions were observed in the PERFECT 
system, we instructed our patients to hold maximum 
voluntary contraction for 6 seconds, and twice as long 
the second time (12 seconds), finally followed by three 
rapid contractions (Figure 1). PFM function assessment 
by the PERFECT system took place monthly for training 
adjustments and progression.18 No additional resources 
were addressed for treating OAB syndrome symptoms 
in addition to PFMT.
We instructed our patients to use the same protocol 
they learned during the outpatient sessions daily but at 
home, in the supine (first month), seated (second month) 
and orthostatic (third month) positions (Figure 2).
Adherence to the PFM training program
To monitor adherence to home exercises, patients com-
pleted an exercise diary. Adherence to the training proto-
col was based on the daily PFM training records performed 
by the patients (three sets of daily exercises). We instruct-
ed patients to record exercises only when they actually 
practiced them. Adherence was expressed as the average 
of series of exercises patients did monthly during the 
treatment period.19 Outpatient attendance at sessions 
was monitored by the physiotherapist accompanying the 
patients during treatment and expressed as an average at 
the end of the three-month treatment.
For the statistical analysis, we used the SPSS software 
version 22.0. For analyzing demographic data, clinical 
traits and adherence to the exercises, we used the Mann-
Whitney test. In order to analyze possible differences 
before and after treatment, we used the Wilcoxon test 
with a significance level of 5%.
results
Twenty-seven (27) patients were included in the period 
between March 2011 and September 2013. Seven women 
did not complete the treatment (35% dropout rate). Rea-
sons reported for dropout were: two patients reported 
difficulties in obtaining release from work; three due to 
family reasons; and another two due to prioritizing the 
treatment of other health conditions. Demographic and 
clinical traits are described in Table 1. 
In comparing the urinary symptoms between the 
initial and final assessments conducted during the treat-
ment, we observed significant improvement in the sever-
ity of UI as assessed in the pad test; in urinary leakage 
and nocturia, as evaluated with the voiding diary; in OAB 
symptoms as assessed by the OAB-V8 questionnaire; and 
in the three domains of quality of life assessment as eval-
uated by the I-QoL questionnaire (Table 2).
A. Pelvic floor muscles during rest B. Pelvic floor muscles during contractions
FIGURE 1 Illustration of pelvic floor muscles at rest (A) and during contraction (B).
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During PFM assessment, we observed improvement 
in muscle function when comparing the initial and fi-
nal assessments conducted during the treatment, eval-
uated with the PERFECT system and the manometer 
(Table 3).
The mean outpatient attendance during outpatient 
PFMT was 18.4±4.6 sessions. Adherence to in-home ex-
ercises (series of exercises completed) was: 78.3±15.5 (30-
82) in the first month; 74.6±16.3 (24-82) in the second 
month; and 76.2±16.0 (24-82) in the third month.
discussion
PFMT is among the types of conservative treatment for 
urinary symptoms. This is a low-cost, first-line treatment 
FIGURE 2 Illustration of patient positioning for performing exercises at home.
TABLE 1 Clinical and demographic characteristics of the patients.
Variables (n=20) Mean (minimum–maximum)
Age (years) 59.9 (41-77)
BMI (kg/m2) 27.4 (21-38)
Duration of symptoms (months) 128.4 (12-420)
Pregnancies (n) 5.1 (2-16)
Parity (n) 3.5 (0-12)
Mann-Whitney; n: sample size; BMI: body mass index.
TABLE 2 Assessment of urinary symptoms (pad test, voiding diary, OAB-V8) and quality of life before and after treatment.
Variables (n=20) Baseline (mean±SD) Final (mean±SD) p
Pad test (g) 19.5±22.2 5.8±9.7 <0.001*
Urinary leakage 2.1±1.6 0.7±1.1 0.005*
Frequency 7.4±2.8 6.7±2.2 0.360
Nocturia 1.6±1.6 0.8±0.9 0.011*
OAB-V8 21.9±7.2 10.0±7.7 <0.001*
Limitations on human behavior 103.2±28.8 135.5±21.3 0.001*
Psychosocial impact 140.5±36.8 170.5±29.2 0.005*
Embarrasment and social constraint 44.5±30.7 59.7±28.3 0.024*
Wilcoxon*; SD: standard deviation; n: sample size; g: grams; OAB-V8: Overactive Bladder Questionnaire; I-QoL: Incontinence Quality-of-Life Questionnaire.
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for women with stress urinary incontinence (SUI).8 Its 
success rates range from 60 to 75%.15,20 
In addressing OAB symptoms, behavioral therapy 
programs appear as first-rate treatments. These programs 
include the association of techniques that aim at minimiz-
ing or even eliminating the symptoms displayed by the 
patient. Behavioral therapy programs include: educational 
program, changes in lifestyle, bladder training and urge 
suppression strategies, encouragement and positive rein-
forcement, programmed urination, PFMT, PFMT with 
biofeedback (BF) and PFMT with electrostimulation.6 In 
our study, we proposed to use only PFMT for the treatment 
of OAB symptoms. We observed a significant improvement 
in PFM function, urinary symptoms and quality of life 
after 12 weeks of outpatient and in-home training.
Studies published in the literature that make use of 
PFMT alone for OAB symptoms are scarce. In our study, 
we observed an improvement in muscle function as mea-
sured by digital palpation (p<0.001) and manometry 
(p<0.001). Wang et al. used the isolated PFMT, training 
with BF, and coupled with electrostimulation without 
combining other resources to suppress urgency and urge 
incontinence. Improvement in PFM function was found 
across all three groups, with greater relevance in the BF 
group. The increase in vaginal contraction pressure was 
105% in the BF group; 78.9% in the PFMT group; and only 
12.6% in the electrostimulation group.21 BF is an adjuvant 
to PFMT and allows patients to observe PFM contractions 
during exercise, thereby improving exercise performance 
and treatment motivation,22-24 which may justify a sig-
nificant improvement in PFM function. 
However, Wang et al.21 do not consider muscle strength 
the best indicator when assessing OAB symptoms. Treat-
ment of overactive bladder symptoms should be evalu-
ated by its effectiveness in reducing urinary symptoms 
and its impact on quality of life. 
In our study, we observed an improvement in urinary 
leakage as assessed by pad test (p<0.001), voiding diary 
(p=0.005), nocturia (p=0.011) and degree of discomfort 
caused by urinary symptoms as assessed by the OAB-V8 
questionnaire (p<0.001). In assessing quality of life, we 
also observed positive results in the three domains evalu-
ated by the I-QoL questionnaire. There was no significant 
reduction in urinary frequency, given that initial values 
were within normal standards, according to the Interna-
tional Urogynecological Association (IUGA)/International 
Continence Society (ICS).1  
Wang et al.21 found urinary symptom reduction rates 
of about 51% in the electrostimulation group, 50% in the 
isolated PFMT group and 38% in the PFMT group with 
BF. The authors found electrostimulation to be superior 
to the other groups. Electrostimulation inhibits detrusor 
activity by directly stimulating the pudendal nerve.25 Bur-
gio et al.26 observed incontinence reduction of about 80% 
in women with urge incontinence by using PFMT with BF. 
In a study with the specific objective of evaluating 
and comparing the effects of oxybutynin, electrostimula-
tion and perineal exercises in the treatment of detrusor 
overactivity, the urge incontinence decreased in all three 
groups (p<0.05) following treatment as assessed by the 
voiding diary. Urgency disappeared in about 63% of pa-
tients in the oxybutynin group; in 52% of patients in the 
electrostimulation group; and in 57% of patients in the 
perineal exercises group. The results were similar between 
the groups (p=0.754). In the subjective evaluation, the 
percentage of women who were satisfied after treatment 
was 77%, 52% and 76%, respectively, in the oxybutynin, 
electrostimulation and perineal exercise groups, with no 
significant differences between them (p=0.142).5
The benefits of short- and long-term physiotherapeu-
tic treatment programs depend on patient adherence.27 
In our study, we observed an outpatient attendance of 
75% and a mean in-home adherence during the 3 month 
treatment of 80%. 
The results from these studies should be compared 
with caution, as there are differences in the inclusion 
criteria and disease definitions across them, as well as 
specific criteria for evaluating cure and improvement in 
symptoms. Most studies combined treatments, which 
makes it difficult to understand how each of the resourc-
es can act individually. In our sample, the patients did 
not receive any information on behavioral orientation. 
TABLE 3 Assessment of the function of pelvic floor muscles (manometry and PERFECT) before and after treatment. 
Variables (n=20) Baseline (mean±SD) Final (mean±SD) p
MVC (cmH2O) 19.7±12.2 26.6±15.8 0.003*
Oxford 2.6±1.1 3.6±0.9 0.001*
Endurance (s) 2.7±1.2 5.2±1.8 <0.001*
Fast 5.3±2.4 8.9±1.5 <0.001*
Wilcoxon; SD: standard deviation; s: seconds; n: sample size; MVC: maximum voluntary contraction.
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There is insufficient evidence to support PFMT in treat-
ing OAB symptoms, since it is unclear how PFM contraction 
can inhibit detrusor contractions. PFMT involves the con-
traction of the puborectalis muscles, as well as the anal and 
external urethral sphincters. Studies have shown that con-
traction of these muscles leads to suppression of detrusor 
contraction.28,29 The studies published in the literature that 
use PFMT for OAB are scarce, and most of them rely on 
the association of different treatment modalities.
Our study is a prospective trial that shows benefits 
of isolated PFMT in improving urinary leakage symptoms, 
nocturia, quality of life and PFM function. Nonetheless, 
randomized controlled trials are needed to further dem-
onstrate and understand how women with OAB symptoms 
can benefit from PFMT.
conclusion
Our results suggest that PFMT with no additional guide-
lines can improve urinary leakage, nocturia, PFM function 
and quality of life in women with OAB symptoms. Still, 
randomized controlled trials using PFMT alone are re-
quired in order to better demonstrate and understand 
how it can act on OAB symptoms. 
resuMo
Treinamento dos músculos do assoalho pélvico nos sin-
tomas da bexiga hiperativa – Um estudo prospectivo 
Introdução: O treinamento dos músculos do assoalho 
pélvico (TMAP) envolve a contração dos músculos pu-
borretal, esfíncteres anal e uretral externo, inibindo a 
contração do detrusor, o que justifica sua utilização no 
tratamento dos sintomas da bexiga hiperativa (BH). 
Objetivo: Verificar os efeitos do TMAP isolado sobre a 
sintomatologia da BH. 
Método: Ensaio clínico prospectivo com 27 mulheres com 
incontinência urinária mista (IUM), com predomínio de 
sintomas de BH e perda ≥ 2 g no pad test. Avaliaram-se: 
função dos músculos do assoalho pélvico (MAP) (palpação 
digital e manometria); sintomas urinários (noctúria, fre-
quência e perda urinária); grau de incômodo dos sintomas 
de BH (Overactive Bladder Questionnaire [OAB-V8]); e 
qualidade de vida (Incontinence Quality-of-Life Question-
naire [I-QoL]). O programa de TMAP consistiu em 24 ses-
sões ambulatoriais (2x/semana + TMAP domiciliar). Os 
testes de Mann-Whitney e Wilcoxon (com nível de signifi-
cância de 5%) foram utilizados para analisar os dados. 
Resultados: Observou-se melhora significativa dos sin-
tomas urinários ao pad test (5,8±9,7; p<0,001); ao diário 
miccional (perda urinária [0,7±1,1; p=0,005] e noctúria 
[0,8±0,9; p=0,011]). Foram observados redução do grau 
de incômodo dos sintomas urinários conforme questio-
nário OAB-V8 (10,0±7,7; p=0,001) e significativos resul-
tados na função dos MAP: Oxford (3,6±0,9; p=0,001), 
Endurance (5,2±1,8; p<0,001), Fast (8,9±1,5; p<0,001) e 
manometria (26,6±15,8; p=0,003). No mais, a qualidade 
de vida teve significativa melhora nos três domínios ava-
liados pelo I-QoL. 
Conclusão: O TMAP sem quaisquer orientações adicio-
nais melhora a sintomatologia, a função dos MAP e a 
qualidade de vida de mulheres com sintomas de BH.
Palavras-chave: incontinência urinária, diafragma da 
pelve, modalidades de fisioterapia. 
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